Effects of EGCG (Epigallocatechin Gallate) in Huntington's Disease (ETON-Study)
NCT01357681, Phase 2, Completed, Charite University, Berlin, Germany
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Effects of EGCG (Epigallocatechin Gallate) in Huntington's Disease (ETON-Study) | ClinicalTrials.gov |
| NCT number | NCT01357681 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Phases | Phase 2 | ClinicalTrials.gov |
| Enrollment | 54 participants, actual | ClinicalTrials.gov |
| Lead sponsor | Charite University, Berlin, Germany | ClinicalTrials.gov |
| Conditions | Huntington Disease | ClinicalTrials.gov |
| Interventions | (2)-epigallocatechin-3-gallate (EGCG), Placebo | ClinicalTrials.gov |
| First posted | 2011-05-23 | ClinicalTrials.gov |
| Last updated | 2015-06-16 | ClinicalTrials.gov |
Registered outcomes 16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change of cognitive functions (UHDRS-Cognition: composite score of Stroop test, Verbal fluency & Symbol Digit Modalities Test) after 12 months in comparison to baseline | Month 0, Month 12 | ClinicalTrials.gov | |
| Secondary | UHDRS Motor Score | Month 0, Month 12 | ClinicalTrials.gov | |
| Secondary | UHDRS Behavioural Score | Month 0, Month 12 | ClinicalTrials.gov | |
| Secondary | UHDRS Functional Assessment | Month 0, Month 12 | ClinicalTrials.gov | |
| Secondary | UHDRS Total Functional Capacity (TFC) | Screening, Month 12 | ClinicalTrials.gov | |
| Secondary | Clinical Global Impression (CGI) | Month 0, Month 12 | ClinicalTrials.gov | |
| Secondary | Depression: Beck Depression Inventory (BDI) | Screening, Month 1, Month 2, Month 3, Month 6, Month 9, Month12, Month 13 | ClinicalTrials.gov | |
| Secondary | Health-related Quality of Life: Short Form (36) Health Survey (SF-36) | Month 0, Month 12 | ClinicalTrials.gov | |
| Secondary | Subjective Well-Being: Satisfaction With Life Scale (SWLS) | Month 0, Month 12, Month 13 | ClinicalTrials.gov | |
| Secondary | Affective Processing: Positive and Negative Affect Schedule (PANAS) | Month 0, Month 12, Month 13 | ClinicalTrials.gov | |
| Secondary | Tonic and phasic Alertness | Month 0, Month 12 | ClinicalTrials.gov | |
| Secondary | Global Cognition: Mini Mental State Examination | Screening, Month 12, Month 13 | ClinicalTrials.gov | |
| Secondary | Quantitative evaluation of motor functions: Qmotor | Month 0, Month 12 | ClinicalTrials.gov | |
| Secondary | Brain atrophy: assessed by magnetic resonance imaging (MRI)-voxel-based morphometry (VBM) | Month 0, Month 12 | ClinicalTrials.gov | |
| Secondary | Pharmacokinetics and tolerability of EGCG | Month 1 - Month 12 | assessment of side effects and determination of blood and cerebrospinal fluid (CSF) levels of EGCG | ClinicalTrials.gov |
| Secondary | Determination of huntingtin expression levels | Screening - Month 13 | Quantification of huntingtin in blood and CSF (optional) | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 3
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Primary outcome | ConductCognition |
| Symbol Coding | Primary outcome | ConductCognition |
| Verbal Fluency | Primary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)